复星医药(02196.HK):复宏汉霖拟为汉霖制药不超1.7亿元融资提供担保
格隆汇9月10日丨复星医药(02196.HK)公告,上海复星医药(集团)股份有限公司控股子公司上海复宏汉霖生物技术股份有限公司拟为其全资子公司上海复宏汉霖生物制药有限公司向上海农村商业银行股份有限公司嘉定支行申请的金总额不超过人民币1.7亿元的融资额度项下债务提供最高额连带责任保证担保。
截至2019年9月10日,包括本次担保在内,公司及控股子公司/单位实际对外担保金额按2019年9月10日汇率(中国人民银行公布的美元兑人民币中间、欧元兑人民币中间价,下同)折合人民币约131.77亿元,占2018年12月31日集团经审计归属于上市公司股东净资产的约47.10%;其中:集团实际为汉霖制药担保金额为人民币1.7亿元。上述集团对外担保已经公司股东大会批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.